Last reviewed · How we verify
AMG 162
AMG 162 is a monoclonal antibody that inhibits RANKL (receptor activator of nuclear factor kappa-B ligand), blocking osteoclast formation and bone resorption.
AMG 162 is a monoclonal antibody that inhibits RANKL (receptor activator of nuclear factor kappa-B ligand), blocking osteoclast formation and bone resorption. Used for Postmenopausal osteoporosis, Prevention of skeletal-related events in patients with bone metastases from solid tumors.
At a glance
| Generic name | AMG 162 |
|---|---|
| Sponsor | Amgen |
| Drug class | RANKL inhibitor monoclonal antibody |
| Target | RANKL (Receptor Activator of Nuclear Factor Kappa-B Ligand) |
| Modality | Small molecule |
| Therapeutic area | Bone metabolism / Oncology |
| Phase | Phase 3 |
Mechanism of action
AMG 162 binds to RANKL, a key cytokine in the RANK/RANKL/OPG pathway that drives osteoclast differentiation and activation. By neutralizing RANKL, the drug reduces bone resorption and increases bone mineral density. This mechanism makes it effective for conditions characterized by excessive bone loss, such as osteoporosis and bone metastases.
Approved indications
- Postmenopausal osteoporosis
- Prevention of skeletal-related events in patients with bone metastases from solid tumors
Common side effects
- Hypocalcemia
- Osteonecrosis of the jaw
- Atypical fractures
- Infections
Key clinical trials
- Denosumab + PD-1 in Subjects With Stage III/ IV Melanoma (PHASE2)
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial (PHASE2)
- A Study for the Evaluation of Efficacy and Safety of Prolia® in Participants With Glucocorticoid-induced Osteoporosis in Mainland China (PHASE4)
- Bone Loss Prevention With Zoledronic Acid or Denosumab in Critically Ill Adults (PHASE2)
- Romosozumab/Denosumab Study for Premenopausal IOP (PHASE2)
- A Study of Denosumab in Multiple Myeloma Patients With Renal Insufficiency (PHASE2)
- Contribution of Bone to Urine Citrate
- The Comparison of Ibandronate and Zoledronic Acid After Denosumab Discontinuation (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AMG 162 CI brief — competitive landscape report
- AMG 162 updates RSS · CI watch RSS
- Amgen portfolio CI